Addition- ally the potential efficacy of pre- pro- and synbiotics in the restoration of healthy gut microbia is described in detail to provide future directions for research.Keywords Chronic kidney disease CKD  Intestinal microbiota  Uremic toxins  Lipopolysaccharides LPS  Immune deregulation  Prebiotic  ProbioticsWei Pan and Yongbo Kang have contributed equally to this work.AbbreviationsBUNBlood urea nitrogen CKDChronic kidney disease CVDCardiovascular disease DMADimethylamineESKD End-stage kidney disease GFR Glomerular filtration rate GIT Gastrointestinal tractGLP-1Glucagon-like peptide 1 GOSsGalacto-oligosaccharides IL-6Interleukin-6ISIndoxyl sulfateLPSLipopolysaccharides NKTNatural killer TPCSP-cresyl sulfatePYYPeptide YYRSResistant starch SCFAsShort-chain fatty acidsIntroductionChronic kidney disease CKD as a frequently life-threat- ening disorder that influences the structure and function of the kidney represents a typical predictor of end-stage kidney Yongbo Kang 1 Faculty of Foreign Languages and Cultures Kunming University of Science and Technology Kunming Yunnan China2 Medical Faculty Kunming University of Science and Technology Kunming Yunnan China3 Genetics and Pharmacogenomics Laboratory Kunming University of Science and Technology Kunming Yunnan Chinadisease ESKD and is badly in need of approaches for pre- vention early detection and treatment .

Annu Rev Pathol Mech Dis 619-48Carrero JJ Stenvinkel P 2010 Inflammation in end-stage renal disease--What have we learned in 10 years Semin Dial 235498-509Harris K Kassis A Major G et al 2012 Is the gut microbiota a new factor contributing to obesity and its metabolic disor- ders J Obes 2012879151Chow J Tang H Mazmanian SK 2011 Pathobionts of the gastrointestinal microbiota and inflammatory disease.

It is clear that inflammatory promoters including graft ischemia time baseline disease and immunosuppressive drugs may facili- tate the breakdown of the gut barrier  .Immune deregulationGut microflora as a cause of inflammationAltered gut bacteria and their products are also associ- ated with systemic inflammation given that higher lev- els of C-reactive protein pentraxin-3 proinflammatory cytokines  sTWEAK sTRAIL S100A12 man- nose-binding lectin and activated complement  were observed in ESRD patients.

ASAIO J 52170-79Niwa T 2011 Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease experimental and clinical effects of oral sorbent AST-120.

J Am Soc Nephrol 271305-313Missailidis C Hallqvist J Qureshi AR et al 2016 Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease.

J Autoimmun 29152-59Farhadi A Banan A Fields J et al 2003 Intestinal barrier an interface between health and disease.

Nephrol Dial Transplant 263759-761Barreto FC Barreto DV Liabeuf S et al 2009 Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

J Am Soc Nephrol 253615-622Soulage CO Koppe L Fouque D 2013 Protein-bound uremic toxins... new targets to prevent insulin resistance and dysme- tabolism in patients with chronic kidney disease.

J Cell Physiol 230122927-2935Lin C-J Pan C-F Liu H-L et al 2012 The role of pro- tein-bound uremic toxins on peripheral artery disease andvascular access failure in patients on hemodialysis.

Lab Investig 91111564-1571Nangaku M Mimura I Yamaguchi J et al 2015 Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients.

